Abstract: A method of solubilizing an analog active agent of the prostaglandin F2?, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment.

Abstract: A method of solubilizing an analog active agent of the prostaglandin F2?, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment.

Abstract: A method of solubilizing an analog active agent of the prostaglandin F2?, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and, a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment.

Abstract: A method of solubilizing an analog active agent of the prostaglandin F2?, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment.

Abstract: The present invention is related to ophthalmic formulations for the treatment of ocular ailments. More specifically, it is related to the pharmaceutical industry in the production of ophthalmic medication for the treatment of ocular hypertension. The advantage of the present invention over other state of the art treatments is that it achieves a composition of Dorzolamide Hydrochloride, Timolol Maleate and Brimonidine Tartrate with excellent properties of stability; it does not give rise to chemical reactions which produce modifications in the active molecules; with no antagonistic effects among the components. The present invention consists of a stable pharmaceutical composition for the treatment of ocular hypertension characterized by consisting of the following excipients: Polyoxyl 40 Stearate, Sodium Borate crystals, Sodium Chloride, Mannitol and Benzalkonium chloride.

Abstract: The present invention is related to the pharmaceutical industry in general and in particular with the pharmaceutical industry of production of ophthalmic compositions. More specifically, the present invention relates to the pharmaceutical industry of production of ophthalmologic compositions for the treating of ocular hypertension. The advantage of the present invention against the present state of the technique is the fulfilling of a synergic effect of its components for the decreasing of ocular hypertension with no antagonistic effect between its components. The present invention consists of a pharmaceutical composition for the treatment of ocular hypertension characterized by comprising a pharmacologically effective amount of dorzolamide, with a pharmacologically effective amount of timolol and a pharmacologically effective amount of brimonidine.

Abstract: The invention relates to a novel solid complex, which is insoluble in an aqueous environment and which, in dry form thereof, can be used to develop novel systems for the sustained release of drugs for ophthalmic use. The invention also relates to a method of preparing said complex. The complex is formulated based on a viscoelastic solution derived from HA (Biovisc®), a therapeutically acceptable drug such as a steroid, quinolone, a non-steroid anti-inflammatory, an immunosuppressor or compatible drug and chitosan, all of which are conjugated such as to produce biodegradable polymer matrices for the treatment of ocular ailments. The invention also relates to a method of preparing the aforementioned matrices. The invention further relates to microspheres and a method of producing same, using the same original materials, in which the therapeutic principle comprises a steroid, quinolone, a non-steroid anti-inflammatory, an immunosuppressor or another drug which is stable and compatible with said system.

Abstract: This invention refers to a matter composition of the type used in the treatment of ophthalmic ailments and specifically refers to an ophthalmic carrier solution based on surface-active, emulsifying, antibacterial, antioxidant, etc. Agents which form a carrier that enwraps or masks an active ingredient such as sodium dyclophenac or other antibiotic agents such as tobracin, gentamicin or timolol sulfate, with the aim of avoiding the problems caused by the topical application of the mentioned active ingredients, such as pain, a burning sensation, irritation and other annoyances for the user.